Skip to main content
PALI logo

PALI · Palisade Bio, Inc. · Financials

Track PALI — free
$1.40 -0.03 (-2.10%) At close · Oct 21
Market Cap
$249.21M
Shares
174.27M
Volume · Oct 21 1.43M Avg daily vol (3M) 2.53M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$0
FY2025 Revenue FY2010–FY2025
Net Income
-$16.78M -16.2%
FY2025 Net Income FY2009–FY2025
Operating Margin
-5228%
FY2023 Operating Margin FY2010–FY2023
Diluted EPS
-$0.30 +97.1%
FY2025 Diluted EPS FY2020–FY2025
Operating Cash Flow
-$10.85M +11%
FY2025 Operating Cash Flow FY2009–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010 FY2009
$500K $0 $0 $250K $0 — $13.52K $15.39K $260K $260K $16.25K $10.42K $18.83K $110K $407.71K $390.63K $733.44K —
$19.57M $10.19M $16M $6.89M $6.55M $2.43M $2.02M $4.06M $3.96M $8.1M $13.16M $12.64M $8.36M $7.29M $6.11M $7.35M $9.16M $5.35M
$14.49M $7.86M $5.8M $6.2M $8.76M $9.31M $6.2M $4.59M $4.56M $5.47M $7.5M $6.53M $9.09M $5.35M $4.25M $5.84M $6.62M $5.03M
— — — — — — — — — — — — — — $256K $256K — —
— — — — — — $63K $95K $102K $189K $176K $197K $211K $119K $110K $83K — —
$6000 — — — $3000 $2000 $3000 $143.86K $185.8K $289.21K $337.51K $345.46K $348.63K $244.73K $211.14K $187.05K $130.75K $88.66K
$35.85M $18.06M $14.86M $13.32M $15.72M $41.85M $9.3M $8.65M $8.52M $13.57M $20.65M $19.17M $17.45M $12.63M $10.56M $13.38M $15.92M $10.47M
-$35.35M -$18.06M -$14.86M -$13.07M -$15.72M -$41.85M -$9.3M -$8.63M -$8.26M -$13.31M -$20.64M -$19.16M -$17.44M -$12.52M -$10.16M -$12.99M -$15.18M -$10.47M
— — — -5228% — — -68764.79% -56071.81% -3176.71% -5118.12% -127027.23% -183896.78% -92581.37% -11385.4% -2491.11% -3325.56% -2070.37% —
-$13.76M — — — -$15.72M -$41.85M -$9.29M -$8.49M -$8.07M -$13.02M -$20.3M -$18.81M -$17.09M -$12.28M -$9.95M -$12.8M -$15.05M -$10.38M
$8000 $10K $12K $15K $13K $2.4M $235K $8920 $7698 $159.07K $1.14M $1.82M $1.62M $1.39M $2699 $821 $2662 $776
$24.16K — — — — — $33.53K $67.73K $78.78K $70.27K $58.84K $69.55K $67.65K $68K $34.15K $60.96K $59.28K $19.61K
$3.41M $1.28M $421K $770K $1.46M $15.24M -$1.03M $280.04K $3.33M -$2.36M -$437.77K -$1.75M -$5.19M -$7.31M $34.94K $471.94K -$3.2M $102.19K
— $0 $0 $0 $0 $0 $1000 — — — $0 $0 $0 $0 $0 $0 — —
-$31.94M -$16.78M -$14.44M -$12.3M -$14.26M -$26.62M -$10.32M -$8.35M -$4.92M -$15.67M -$21.07M -$20.9M -$22.63M -$19.83M -$10.12M -$12.52M -$18.39M -$10.36M
— — — -4920% — — -76346.15% -54252.64% -1894.08% -6025.38% -129721.85% -200671.03% -120154.75% -18028.97% -2482.54% -3204.74% -2507% —
-$11.23M — -$14.44M -$12.32M -$14.55M -$26.62M -$10.32M — — — — — — — — — — —
-$10.97M — — — — — -$16.26M -$8.36M -$4.93M -$15.67M -$21.07M -$20.91M — — — — — —
USD/shares $0.65 -$0.30 -$10.19 -$27.01 -$247.95 -$2,144.25 -$2,790.00 — — — — — — — — — — —
USD/shares $0.65 -$0.30 -$10.19 -$27.01 -$247.95 -$2,546.10 -$2,790.00 — — — — — — — — — — —
shares — 55.67M 1.42M 456.01K 58.69K 12.41K 3699.16 488.3187 145.1602 2903.2049 1854.6649 1553.2809 19.35K 16.06K 12.92K 10.74K — —
shares — 55.67M 1.42M 456.01K 58.69K 12.46K 3699.16 488.3187 145.1602 2903.2049 1854.6649 1553.2809 19.35K 16.06K 12.92K 10.74K — —
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current operating lease liabilities 2025-12-31 USD 0 10-K filed 2026-03-20
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
248,069,792.00×
Peer median 5.88×
EV/EBIT
—
Peer median 9.16×
P/E (TTM)
—
Peer median 11.00×

Peer medians compare against the 330 similar-size Biotechnology companies (of 560 listed).

Valuation over time computed as of each quarter's filing date

Key facts CIK 1357459 CUSIP 696389402 13F (30d) 6 filings 6 filers Visit website Investor relations